A Cancer Research UK first time in human phase I trial of IMA950 (novel multi peptide therapeutic vaccine) in patients with newly diagnosed glioblastoma by Rampling, Roy et al.
 
 
 
 
Rampling, R. et al. (2016) A Cancer Research UK first time in Human 
Phase I Trial of IMA950 (novel multi peptide therapeutic vaccine) in 
patients with newly diagnosed glioblastoma. Clinical Cancer Research, 
22(19), pp. 4776-4785. (doi:10.1158/1078-0432.CCR-16-0506) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/122342/ 
     
 
 
 
 
 
 
Deposited on: 08 August 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
CONFIDENTIAL  Running Title: IMA950 Phase I Trial Final Results 
 
Page 1 of 28 
 
 
A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel 
Multi-Peptide Therapeutic Vaccine) in Patients with Newly Diagnosed 
Glioblastoma  
Roy Rampling1, Sharon Peoples2, Paul J. Mulholland3, Allan James1, Omar Al-Salihi4, 
Christopher J. Twelves5, Catherine McBain6, Sarah Jefferies7, Alan Jackson8, Willie 
Stewart9, Juha Lindner10, Sarah Kutscher10, Norbert Hilf10, Lesley McGuigan11, Jane 
Peters11, Karen Hill11, Oliver Schoor10, Harpreet Singh-Jasuja10, Sarah E. Halford11, James 
W.A. Ritchie11 
 
1. University of Glasgow, Beatson West of Scotland Cancer Centre, 1053 Great Western 
Road, Glasgow, G12 0YN UK.  
2. Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, UK.  
3. Department of Oncology, University College London Hospitals, 1st Floor Central, 250 
Euston Road, London, NW1 2PG, UK.  
4. Adult Neuro-Oncology, Southampton University Hospitals NHS Trust, Tremona Road, 
Southampton, SO16 6YD, UK. 
5. Cancer Research UK Clinical Centre, St James's University Hospital, Leeds, LS9 7TF, 
UK.  
6. The Christie NHS Foundation Trust, Wilmslow Road, Withington, Manchester, M20 4BX 
UK. 
7. Cambridge Cancer Trials Centre, Oncology Clinical Trials, Addensbrooke's Hospital, 
Hills Road, Cambridge, CB2 0QQ, UK. 
8. Wolfson Molecular Imaging Centre, University of Manchester, 27 Palatine Road, 
Manchester, M20 3LJ, UK. 
CONFIDENTIAL  Running Title: IMA950 Phase I Trial Final Results 
 
Page 2 of 28 
 
 
9. Department of Neuropathology, The Queen Elizabeth University Hospital, 1345 Govan 
Road, Glasgow, G51 4TF, UK. 
10. Immatics Biotechnologies GmbH, Paul-Ehrlich-Str. 15, 72076 Tübingen, Germany.  
11. Cancer Research UK Centre for Drug Development, Angel Building, 407 St John 
Street, London, EC1V 4AD, UK. 
 
Running Title: IMA950 Phase I Trial Final Results 
 
Journal for submission: Clinical Cancer Research 
Article type: Cancer Therapy: Clinical 
Invited article: No 
 
Keywords: IMA950, Phase I study, therapeutic cancer vaccine, glioblastoma, 
immunotherapy 
 
Funding: This work was supported by grant C222/A11422 from Cancer Research UK. This 
work was also managed and sponsored by the Cancer Research UK Centre for Drug 
Development. Immatics Biotechnologies provided pharmacodynamic assay support and 
supplied IMA950 for this study. 
 
Corresponding author: James W.A. Ritchie, Cancer Research UK Centre for Drug 
Development, Angel Building, 407 St John Street, London, EC1V 4AD, UK; e-mail:  
james.ritchie@cancer.org.uk; Telephone: +44 1367 240373; FAX: +44 20 3357 3182  
CONFIDENTIAL  Running Title: IMA950 Phase I Trial Final Results 
 
Page 3 of 28 
 
 
 
Trial registration ID: NCT01222221 
 
Conflicts of interest Statement: Norbert Hilf, Sarah Kutscher, Juha Lindner, Oliver Schoor 
and Harpreet Singh are current or past employees of Immatics Biotechnologies. Sarah 
Kutscher, Norbert Hilf, Oliver Schoor and Harpreet Singh have stock ownership interests in 
Immatics Biotechnologies. Sarah Kutscher, Norbert Hilf, Oliver Schoor, Harpreet Singh 
have intellectual property interests in Immatics Biotechnologies. Sarah Kutscher, Norbert 
Hilf, Oliver Schoor and Harpreet Singh have received either travel, accommodation or other 
expenses from Immatics Biotechnologies during the previous two years. Harpreet Singh 
has a leadership role at Immatics Biotechnologies. Other authors disclosed no conflicts of 
interest. 
 
Presented in abstract form at the European Society for Medical Oncology 2012 Congress, 
Vienna, Austria, September 28 to October 2, 2012; and European Society for Medical 
Oncology 2014 Congress, Madrid, Spain, September 26 to 30, 2014. 
 
Word count (excluding cover pages, references, tables and figures): 5000 
Number of tables (excluding supplementary materials): 2 
Number of figures (excluding supplementary materials): 4 
  
CONFIDENTIAL  Running Title: IMA950 Phase I Trial Final Results 
 
Page 4 of 28 
 
 
Statement of Translational Relevance 
Survival rates for patients with glioblastoma (GBM) are abysmal, with median overall 
survival of approximately 15 months. Immunotherapy of GBM is a promising area of 
investigation, although challenges around identification of novel and immunogenic target 
antigens exist. IMA950 is a GBM specific vaccine comprising 11 tumor-associated peptides 
(TUMAPs) developed to address this challenge. We have performed a phase 1 safety and 
immunogenicity study in newly diagnosed GBM patients using IMA950 plus GM-CSF 
alongside standard of care chemo-radiotherapy. Our results demonstrate that IMA950 is 
well tolerated with 90% of patients having a CD8+ T-cell immune response to at least one 
TUMAP, with 50% responding to two or more TUMAPs. No effect of pre-treatment 
regulatory T-cell levels on IMA950 immunogenicity was found and steroids did not appear 
to affect immune responses to the TUMAPs. This data provides evidence to support further 
development and optimization of IMA950 together with other immunotherapies for GBM.  
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Abstract 
PURPOSE: To perform a two-cohort, phase 1 safety and immunogenicity study of IMA950 
in addition to standard chemo-radiotherapy (CRT) and adjuvant temozolomide in patients 
with newly diagnosed glioblastoma (GBM).   IMA950 is a novel GBM specific therapeutic 
vaccine containing 11 tumor-associated peptides (TUMAPs), identified on human leukocyte 
antigen (HLA) surface receptors in primary human GBM tissue. 
EXPERIMENTAL DESIGN: Patients were HLA-A*02 positive and had undergone tumor 
resection. Vaccination comprised 11 intradermal injections with IMA950 plus GM-CSF over 
a 24 week period, beginning 7-14 days prior to initiation of CRT (Cohort 1) or 7 days post 
CRT (Cohort 2). Safety was assessed according to NCI CTCAE Version 4.0 and TUMAP 
specific T-cell immune responses determined. Secondary observations included 
progression-free survival (PFS), pre-treatment regulatory T-cell (Treg) levels and the effect 
of steroids on T-cell responses. 
RESULTS: Forty five patients were recruited. Related adverse events included minor 
injection site reactions, rash, pruritus, fatigue, neutropenia and single cases of allergic 
reaction, anemia and anaphylaxis. Two patients experienced Grade 3 dose limiting toxicity 
of fatigue and anaphylaxis. Of 40 evaluable patients, 36 were TUMAP responders and 20 
were multi-TUMAP responders, with no important differences between cohorts. No effect of 
pre-treatment Treg levels on IMA950 immunogenicity was observed and steroids did not 
affect TUMAP responses. PFS was 74% at 6 months and 31% at 9 months. 
CONCLUSION: IMA950 plus GM-CSF was well tolerated with the primary immunogenicity 
endpoint of observing multi-TUMAP responses in at least 30% of patients exceeded. 
Further development of IMA950 is encouraged. 
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Introduction 
GBM, the most aggressive central nervous system tumor, develops from glial tissue of the 
brain and spinal cord (1). Newly diagnosed GBM is an orphan disease with 100% mortality 
and a median overall survival (OS) of only 14.6 months (2). Standard first-line therapy 
comprises maximal safe tumor resection, followed by concomitant chemo-radiotherapy 
(radiotherapy plus daily temozolomide; CRT) and six 28-day cycles of adjuvant 
temozolomide (TMZ) (2). Although the incidence is relatively low, around 3 to 4 cases per 
100,000 population (3), GBM affects patients of all ages and there is a large unmet medical 
need for improved first-line therapy. Furthermore, there is evidence to suggest that the 
overall incidence of GBM is rising over time and will continue to increase in an ageing 
population (4, 5).  
IMA950 is an immunotherapeutic multiple-peptide vaccine specifically developed to treat 
GBM (6). It contains 11 tumor-associated peptides (TUMAPs) that are presented by a 
majority of GBMs on human leukocyte antigen (HLA) surface receptors. IMA950 is 
designed to trigger the immune system by activation of TUMAP-specific cytotoxic T cells. 
Once activated, these cells are postulated to find and destroy malignant tumor cells 
presenting the cognate TUMAPs. By vaccinating with 11 TUMAPs simultaneously there is 
an increased probability that a multi-clonal, broad yet highly specific T-cell response can be 
mounted against tumor cells thus hindering potential tumor escape mechanisms. 
The primary objectives of this first time in human study were to assess the safety, 
tolerability and immunogenicity of IMA950 plus GM-CSF given alongside standard therapy 
in newly diagnosed GBM patients. 
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Patients and Methods 
Patients 
Eligible patients had histologically or cytologically proven GBM, an operable tumor which 
had already been maximally resected, were at least 18 years of age, human leukocyte 
antigen (HLA) A*02 positive and hepatitis B core antigen seronegative; had a World Health 
Organization (WHO) performance status 0 or 1, a life expectancy of at least 30 weeks and 
were expected to complete standard CRT and six 28 day cycles of adjuvant TMZ. Key 
exclusion criteria included: receipt of any prior GBM treatment apart from surgery, 
vaccination within 2 weeks or having taken dexamethasone at a dose >4 mg/day within 7 
days prior to the first IMA950 plus GM-CSF vaccination, a history of serious cardiac or 
autoimmune disease or any condition which might interfere with the patient’s ability to 
generate an immune response. This study was conducted in accordance with the principles 
of International Conference on Harmonisation (ICH) Good Clinical Practice (GCP), the 
requirements of the UK Clinical Trials regulations (SI 2004/1031 and SI 2006/1928), and 
the Declaration of Helsinki. The study protocol, patient information sheet and informed 
consent form were approved by the Sponsor’s Central Institutional Review Board, and the 
appropriate Research Ethics Committee prior to study conduct. After a full explanation of 
the study protocol, written informed consent was obtained from all patients before being 
enrolled. 
IMA950 Vaccine 
IMA950 is a novel multi-peptide GBM specific vaccine comprising 11 HLA binding TUMAPs 
and one viral marker peptide, identified on HLA surface receptors in primary human GBM 
tissue, as described previously (6). Supplementary Table S1 gives an overview of the 
TUMAP source antigens and their respective expression levels found in primary GBM 
CONFIDENTIAL  Running Title: IMA950 Phase I Trial Final Results 
 
Page 8 of 28 
 
 
tumor samples. Selected TUMAPs are designed to activate TUMAP-specific CD8+ 
cytotoxic and CD4+ helper T lymphocytes, which then recognize cognate TUMAPs 
presented by GBM tumor cells and effect a targeted immune response. Nine of the 11 
TUMAPs were selected on the basis of their functional relevance, association with the 
human leukocyte antigen HLA-A*02, over-expression in GBM and proven immunogenicity 
using in vitro T-cell assays. The other two TUMAPs contained in IMA950 are both HLA 
class II-binding peptides designated IMA-BIR-002 and IMA-MET-005. IMA-BIR-002 has the 
capacity to activate CD4+ helper T cells (7) and potentially cytotoxic T lymphocytes (CTLs). 
IMA-MET-005 contains a known HLA class I epitope, which was elongated based on the 
natural sequence of c-Met (known oncogene and potential marker of GBM stem cells (8), 
with the capacity to activate helper T cells (9) and, after processing, CTLs). An additional 
non-TUMAP (IMA-HBV-001) was included in IMA950 derived from Hepatitis B virus (HBV) 
core antigen, to act as a positive control from a “non-self” antigen in cases where no 
vaccine-induced T-cell responses to TUMAPs from “self” antigens are observed. 
Study Design and Treatment 
Vaccination comprised fixed doses of recombinant granulocyte macrophage-colony 
stimulating factor (GM-CSF; 75 μg), a commonly used immunomodulator (10), followed by 
IMA950 (4.96 mg, 413 μg each peptide) injected intradermally (i.d.) at 11 time points over a 
24 week period. All patients received the same vaccination schedule comprising an 
“Induction Phase” (VIP) of six intensive vaccinations (V1-V6), followed by a “Maintenance 
Phase” (VMP) of five vaccinations (V7-V11) over a longer period. Forty five patients with 
newly diagnosed GBM were entered into one of two Cohorts that differed by virtue of the 
first vaccination given at different time points alongside standard therapy (rationale for 
recruiting at least 20 patients per cohort is given in Supplementary Table S2). In Cohort 1, 
the VIP started 7 to 14 days before the scheduled onset of CRT to ensure that at least the 
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first three vaccinations (Days 1, 2, 3) were administered prior to the start of CRT. In Cohort 
2, the VIP started a minimum of 7 days after the final dose of CRT and 28 days (+7 days) 
prior to the first scheduled dose of adjuvant TMZ. This ensured that all six vaccinations in 
the VIP were administered at least a week after the end of immunosuppressive CRT and 
completed a week prior to the start of adjuvant TMZ. Three safety observation periods of 21 
days were included after 1, 3 and 6 patients had completed 21 days of treatment prior to 
opening to general recruitment. CRT comprised 54 to 60 Gray in 30 daily fractions over 6 
weeks with concomitant daily TMZ, 75 mg/m2 throughout. Adjuvant TMZ, 150-200 mg/m2 
for 5 days began 35 (+/-7 days) following the last fraction of radiotherapy, repeated every 
28 days for a total of 6 cycles.  See Supplementary Fig. S1 for a detailed overview of the 
treatment and assessment schedule. 
Patient Monitoring and Assessment 
The primary study endpoint of safety and tolerability was assessed according to National 
Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 
4.0. Disease was assessed using MacDonald criteria (11) with the secondary endpoint of 
progression free survival evaluated at 6 (PFS-6) and 9 months (PFS-9) from date of 
surgery. Any clinical complete (CR) or partial response (PR) to therapy was confirmed by 
an independent neuro-oncologist and radiologist. Although not an endpoint of the study, 
survival data was collected for two years after the final patient had received their first 
vaccination. The cut-off date for analysis was February 18, 2015. 
Pharmacodynamic Analysis 
A co-primary endpoint was determining the number of patients showing patient individual 
T-cell responses directed against TUMAPs contained in IMA950 at one or more 
post-vaccination time points, as determined by HLA multimer analysis (12, 13). Individual 
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patient peripheral blood mononuclear cell (PBMC) samples were pooled in order to ensure 
sufficient viable PBMCs for multimer analysis as follows: “Pre-vaccination” (PBMC samples 
1 and 2), “post-vaccination 1” (PBMC samples 3 and 4), “post-vaccination 2” (PBMC 
samples 5 and 6) and “post-vaccination 3” (samples 7 and 8). See Supplementary Fig. S1 
for further details. Tetramer staining for each TUMAP and control antigens were performed 
after an in vitro sensitization as described previously (13). Exemplary gating is shown in 
Supplementary Fig. S2. A positive vaccine-induced multimer CD8 T-cell response for any 
specific post-vaccination time point of a given antigen and patient was assigned if the 
following criteria were met: an above threshold immune response (assessed by five 
independent, trained and blinded jurors and according to Association for Cancer 
Immunotherapy recommendations (14)) and an at least four-fold higher frequency of 
multimer positive CD8 T cells (normalized to total CD8 T cells) compared to the respective 
pre-vaccination time point. Based on prior clinical experience, at the time of study inception, 
with similar multi-peptide vaccines (13), study success criteria were defined as either ≥ 30% 
multi-TUMAP response or > 60% single TUMAP response in the study population. Further 
development would be recommended if either criterion was met. Secondary outcome 
measures included Treg levels (defined as CD3+CD4+CD8-CD25highCD127lowFoxp3+ 
lymphocytes (15)) pre- and post-vaccination, and correlation of steroid dose with observed 
T-cell responses. Research analysis examined the kinetics of TUMAP immunogenicity, 
effect of O6-Methylguanine DNA methyltransferase (MGMT) promoter methylation status on 
PFS and exploring the possible effects of vaccination on observed disease pseudo-
progression and pseudo-regression measured using a standardized diffusion-weighted 
(DWI) and perfusion-weighted (PWI) magnetic resonance imaging (MRI) protocol. Pseudo-
progression was defined as an apparent increase in the enhancing tumor (>25%) on an 
early reference scan followed by a reduction in subsequent scans (assessed at Week 25 
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onwards), with no associated clinical deterioration. Pseudo-regression was assessed using 
an inverse definition. It was recommended that patients continue on therapy until the true 
clinical diagnosis was clarified. Although this design pre-dated that of recently published 
guidance, suggesting that patients continue the immunotherapy regimen for 3 months prior 
to PD confirmation (16), it is generally in line with these recommendations. 
Statistical Analysis 
For the pharmacodynamic analysis, several different methods were used to calculate 
statistical significance depending on the type of data being examined. All statistical analysis 
was performed using Prism version 6.02 software (GraphPad Software Inc., La Jolla, 
California, USA). Two-tailed non-parametric Mann-Whitney test was used to determine 
differences between independent groups under examination. This included, for example, 
the number of vaccine induced TUMAP responses per patient between Cohorts and 
frequency of Treg as a percentage of total lymphocytes for a given patient compared 
between Cohorts. Fisher’s exact test was used to analyze contingency tables. This included 
a comparison of the proportion of patients showing a TUMAP response between Cohorts. 
Non-parametric Spearman’s rank correlation test was used to analyze dependence 
between two variables such as immune responses and regulatory T cell levels. 
The Kaplan-Meier method was used to generate survival curves and estimate OS rates.  
Log rank test was used to compare the survival distributions between groups of patients 
that included censored data.  
Statistical analysis of imaging parameters was performed using a one-way ANOVA analysis 
with post hoc intergroup analysis using Tukey’s test, due to a significant number of datasets 
being unavailable for analysis.  
Results 
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Patient Demographics  
Table 1 provides an overview of patient demographics. Of 138 patients screened, 53% 
were HLA-A*02 positive, which is in the expected range for a United Kingdom population 
(17). Reasons for non-entry of 26 HLA-A*02 patients is given in Supplementary Table S3. 
Forty five patients were recruited into the study; 22 in Cohort 1 and 23 in Cohort 2. Forty 
patients were immune evaluable, with 39 evaluable for clinical activity assessment. This 
discrepancy is a result of two patients being lost for follow up between blood sample 6 and 
week 25 scan (see Supplementary Fig. S1), including one patient that was immune 
evaluable. The overall median age was 53 years (range 20-75 years) with no meaningful 
difference between cohorts. All patients had WHO performance status (PS) 0 or 1 at 
recruitment. A larger proportion of patients in Cohort 2 (65%) had a PS of 1 compared to 
Cohort 1 (27%), most likely due to Cohort 2 patients having undergone treatment with CRT. 
As expected, the lymphocyte count on patient entry was lower in Cohort 2 (0.80x109/L) 
compared to Cohort 1 (1.49x109/L) reflecting the effect of concomitant TMZ in the former. 
Of the 38 patients evaluable for MGMT promoter methylation testing, 11 (29%) were 
positive for methylated promoter, 8 of 19 (42%) in Cohort 1 compared to 3 of 19 (16%) in 
Cohort 2. 
Safety  
All patients received at least one vaccination and were evaluated for safety (see Table 2 for 
the most commonly reported adverse events (AEs), regardless of causality). Injection site 
reaction (ISR) was the most frequent AE, and most common study drug related AE with 81 
instances reported in 26 patients (12/22 patients in Cohort 1 and 14/23 patients in Cohort 
2). The majority of ISRs were grade 1 (24 out of 26 patients) with only two instances of 
grade 2 events. Thirty one patients experienced at least one serious adverse event (SAE), 
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one of which was a death unrelated to the study drug. The most frequently reported SAEs 
were seizure in 8 patients followed by thromboembolic events in 6 patients, none was study 
drug related. Investigators considered 4 SAEs to be related to the study drug including two 
cases of grade 4 neutrophil count decrease and one case each of grade 3 fatigue and 
anaphylaxis. The related SAEs of anaphylaxis and fatigue were both considered dose 
limiting toxicities. There were no unexpected differences in the safety profiles observed in 
the two cohorts.  
Pharmacodynamics 
Thirty six of 40 immune evaluable patients (90%) were TUMAP responders, with 20 (50%) 
responding to more than one TUMAP (Fig. 1A). The pre-defined primary immunologic 
endpoint for recommending further development (≥60% single or ≥30% multi TUMAP 
responders) was therefore reached for the total immune evaluable study population and 
each of the two individual study cohorts. In Cohort 1, 9/19 (47%) evaluable patients 
responded to multiple TUMAPs, with a further 9 (47%) responding to a single TUMAP. 
Similarly, in Cohort 2, 11/21 (52%) evaluable patients had multiple TUMAP responses and 
a further 7 (33%) had a single response. Although the number of vaccine induced 
responses per patient in Cohort 2 appeared to be greater than in Cohort 1 (an arithmetic 
mean of 2.2 in Cohort 2 versus 1.6 in Cohort 1), this was not statistically significant (p=0.3; 
Mann Whitney test; Fig. 1B). Immune response kinetics showed a predominant onset of 
vaccine-induced TUMAP responses in the post-vaccination 1 sample PBMC pool, with 47 
(61%) being detected at this time point (Fig. 2A). This was also true for each cohort. In 
addition, 24 out of 77 (31%) of vaccine-induced TUMAP responses were already detectable 
pre-vaccination and were boosted at least four-fold by administration of IMA950 plus GM-
CSF (data not shown). The majority of vaccine-induced TUMAP responses were detectable 
at one post-vaccination assay time point only (61%, 52/77 immune responses; Fig. 2A) and 
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were of relatively low magnitude (see Supplementary Fig. S3 for exemplary data). The 
proportion of vaccine induced TUMAP responses detected at only one post-vaccination 
assay time point was significantly higher (p=0.025; Fisher’s exact test) in Cohort 1 (25/30 
immune responses; 83%) than in Cohort 2 (27/47 immune responses; 57%) (Fig. 2B). No 
apparent differences in TUMAP responses were noted between patients who were and 
were not receiving concomitant steroid treatment (data not shown).  
Twenty five immune evaluable patients (63%) responded to the “non-self” viral antigen, 
IMA-HBV-001 (13) and was by trend, associated with the number of vaccine-induced 
TUMAP responses (p=0.117 by Wilcoxon test; data not shown). There was also a trend for 
the proportion of IMA-HBV-001 responders to be enriched within the multi-TUMAP 
responder fraction of patients (p=0.191 by Fisher’s exact test; data not shown). 
There was no correlation between pre-treatment Treg levels and number of vaccine-induced 
TUMAP responses overall (Fig. 3A) or within either cohort of patients (Fig 3B and C). A 
comparative analysis of study cohorts revealed that pre-treatment Treg levels normalized to 
lymphocytes were significantly increased (p=0.0003 by Wilcoxon test) in Cohort 2 
compared to Cohort 1 (Fig. 3D).  
In order to explore possible effects of vaccination on observed pseudo-progression and 
pseudo-regression of disease, DWI and PWI was performed alongside standard gadolinium 
MRI scans. Cohort 1 patients showed increases in apparent diffusional coefficient (p<0.05), 
following CRT (see Supplementary Fig. S4).  Over the same period, PWI parameters 
showed a trend (albeit not statistically significance) towards increased T1 values, contrast 
transfer coefficient (Ktrans) and total enhancing volume (ve) with an associated decrease in 
plasma volume (vp) between scans 1 and 2 (data not shown). 
Clinical Activity  
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Twenty nine of 39 evaluable patients were progression free at 6 months (PFS-6 of 74.4%) 
with 12 continuing to be progression free at 9 months (PFS-9 of 30.8%). Stable disease 
(SD) was confirmed for 11 evaluable patients (28.2%) at Week 40. One patient with 
residual disease at baseline had a partial response (PR) at Week 40, with tumor size 
decreasing from 357 mm2 at baseline to 25 mm2 at week 17, being maintained until they 
went off study. Four patients with SD and the patient with PR at Week 40 had MGMT 
promoter methylation (5/11 patients with a methylated MGMT promoter; 45.5%). Five other 
patients with SD at Week 40 had unmethylated MGMT promoters (5/27 patients with an 
unmethylated MGMT promoter; 18.5%). Eleven patients out of an evaluable 38 (29%) had a 
methylated MGMT promoter, which conferred a significant survival advantage (28.3 versus 
14.8 months; p=0.025 using Log-rank test; data not shown).  
As of the cutoff date (18-Feb-15), median OS for the study was 15.3 months (Fig. 4A) with 
no significant differences between the cohorts or those patients that responded to multiple 
TUMAPs compared to those that did not respond or to one TUMAP only (Fig. 4B). 
Interestingly, patients experiencing one or more ISRs had a significantly improved (p = 
0.0001; hazard ratio 0.33) median OS of 26.7 months compared to 13.2 months for those 
that did not (Fig. 4C). The median age of patients in the ISR group was significantly lower 
than that of the non-ISR (47 versus 57 years respectively; p = 0.023 by Mann Whitney test). 
Imaging parameters in patients displaying ISRs showed no significant difference. However 
in Cohort 2 ISR was associated with lower Ktrans (p <0.05), vp (p<0.01), ve (p<0.05) and rate 
constant Kep (p<0.05) values at baseline.  
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Discussion 
In the majority of treated GBM patients, IMA950 produced antigen specific peripheral CD8+ 
T-cell immune responses to the TUMAPs contained within the vaccine, with a relatively 
benign drug related toxicity profile comprising mainly minor injection site reactions. The two 
cohort study design was used to help define the most biologically effective and clinically 
feasible administration schedule of IMA950 for subsequent development as determined by 
the level of vaccine induced TUMAP specific immune responses for each schedule. 
However, it does not allow direct comparison of clinical efficacy between cohorts since 
recruitment was not randomized nor was the trial prospectively powered to make such a 
comparison. Both cohorts presented challenges that had the potential to interfere with 
successful vaccination and the mounting of a measurable TUMAP specific immune 
response. In Cohort 1, there was a risk that CRT could be immunosuppressive (18, 19) and 
interfere with the induction and maintenance of TUMAP specific CD8+ T cells. Whereas in 
Cohort 2 there was the possibility that following completion of CRT, patient lymphocyte 
counts would be depleted and have lost the ability to mount a detectable immune response 
to IMA950. Indeed, immune data showed that Cohort 1 patients had a decreased detection 
rate of vaccine induced TUMAP responses at later time points (Fig. 2), suggesting that CRT 
may interfere with the induction and maintenance of antigen specific CD8+ T cells. The 
greater number and improved durability of TUMAP responses in Cohort 2 suggests that 
lymphocyte depletion caused by CRT is either insufficient to hinder induction of antigen 
specific CD8+ T cells or can be recovered sufficiently rapidly to support their expansion.  
Treg are a potent immunosuppressive cell population (20) that may interfere with the 
immunogenicity of cancer vaccines (21). Given this, an additional key biological endpoint of 
this study was to explore the effect of pre-treatment Treg levels on the immunogenicity of 
IMA950. There was no correlation between pre-treatment Treg levels (relative to the overall 
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lymphocyte population) and the number of vaccine induced TUMAP responses for the 
overall group of immune evaluable study patients. This result is similar to previous reports 
in other GBM vaccine studies (22, 23). There was a significant increase in the Treg levels at 
the start of vaccinations in Cohort 2 compared to Cohort 1, likely indicating a relative 
increase of Treg compared to other lymphocyte subpopulations as a result of the preceding 
CRT (24). The importance of this finding is unclear given that there were more 
vaccine-induced immune responses in Cohort 2. 
The overall number of immune evaluable patients responding to multiple TUMAPs in this 
study (50%) exceeded that demonstrated for other similar vaccine products (13) such as 
IMA901, which had a multi-TUMAP response rate of 26%. In contrast to that found with 
IMA901, there was no apparent correlation between the number of TUMAP responses and 
improved survival (Fig. 4B). However, there are key differences between this study and that 
of IMA901. IMA901 comprises different TUMAPs, selected specifically for the treatment of 
renal cell carcinoma (RCC) patients and the IMA901 study was conducted in the absence 
of potentially confounding standard of care therapy. Low dose cyclophosphamide (shown to 
decrease the number and function of Treg (25, 26)) was also used alongside GM-CSF to 
further enhance immune response potential. In addition, RCC is known to be an 
immune-responsive tumor type (27), whereas immunotherapy for GBM is still in its infancy. 
Indeed, cancer vaccine immunotherapy strategies for GBM patients require considerable 
refinement due to the challenges posed by immune resistance and suppression in this 
tumor type (28). Multiple immunosuppressive mechanisms are likely to be important in 
GBM including, enhanced secretion of immunosuppressive factors after exposure to 
standard therapy (29), induction of tumor infiltrating lymphocytes and Treg activity (30), as 
well as immune checkpoint pathways such as PD-1/PD-L1 and CTLA-4 (31, 32). 
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The aim of administering adjuvant(s) alongside therapeutic vaccines is to attempt to 
augment immune response and overcome immune suppression by either: moving the 
immune response toward Th1 or Th2 immunity, activating innate immunity or to serve as a 
local repository for prolonged antigen release and protection from degradation. In this study 
we utilized GM-CSF as an adjuvant based on the principle that it should enhance effective 
priming of T-cell responses (33, 34) and the fact that it had been successfully applied in late 
stage clinical trials (35). There is evidence to suggest that in some circumstances at least, 
GM-CSF may not significantly enhance immune responses and may even be detrimental 
(36).  Even so, an earlier meta-analysis of published trials suggests that low-dose GM-CSF 
(40-80 μg for 1-5 days) given s.c. or i.d. at the site of vaccination enhances the cellular 
immune response, while high-dose, systemic treatment (>=100 μg) does not increase the 
efficacy of a peptide vaccine due to expansion of immune-inhibiting MDSCs (10). Based on 
this evidence, we opted for a fixed dose of 75 μg GM-CSF given i.d. prior to vaccination 
with IMA950.  In light of the relatively low magnitude and transient immune responses, 
enhancement of the vaccination regimen, including selection of the most effective adjuvant 
partner(s), is necessary; for example by using alternate or additional adjuvants such as 
locally applied poly-ICLC (37), imiquimod (38) or systemically administering CD40 ligand 
(39) or cyclophosphamide (40). Combining cancer vaccines such as IMA950 with immune 
checkpoint inhibitors such as anti-PD1/PD-L1 or anti-CTLA4 antibodies should also be 
expected to enhance anti-tumor immune responses. This is based on the rationale that 
overcoming local immune suppression and T cell anergy by checkpoint blockade can be 
limited by the specificity/size of the pre-existing T cell population and the fact that some 
tumors are relatively non-immunogenic. Indeed, preclinical and clinical data is beginning to 
emerge demonstrating that the anti-tumor activity of immune checkpoint blockade can be 
enhanced by vaccination (41, 42). 
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The observation that patients experiencing one or more ISRs had improved survival and 
were generally of younger age, suggest that ISR may be a prognostic marker for a patient 
population with an inherently healthier immune system (43). This is supported by the 
significantly different imaging features in Cohort 2 patients experiencing ISRs whose tumors 
showed less vascularity and reduced angiogenesis associated vascular permeability. 
Although this was an unplanned and retrospective analysis, a contribution of the vaccine to 
patient survival for those with a more vigorous immune system cannot be ruled out and 
could be investigated in future randomized studies that might include a non-specific 
immunogen. In addition, methylation of MGMT promoter conferred a survival advantage for 
GBM patients, as previously reported (44). 
A key factor that will need to be considered during the future development of IMA950 and 
therapeutic cancer vaccines more generally is the need to continue vaccination even after 
the disease appears to be progressing. Unlike conventional cancer chemotherapy, the 
effect of cancer immunotherapies is not directly on the disease but rather on the immune 
system which leads to a cellular immune response followed by tumoricidal biological activity 
and potentially improved patient survival (45). This can lead to non-typical patient survival 
curves and misinterpretation of study results. Given this, chronic vaccination beyond 
disease progression, and potentially during subsequent therapy, will need to be carefully 
planned as part of future positioning alongside other therapy for the treatment of GBM.   
IMA-HBV-001 was also included in the IMA950 vaccine to act as a positive control in cases 
where no vaccine-induced T cell responses to TUMAPs from “self” antigens are observed. 
There was a trend (albeit not reaching statistical significance) for patients mounting an 
immune response toward IMA-HBV-001 also to respond to one or more TUMAP, supporting 
its use as a general immunogenicity marker. However these findings also suggest that IMA-
HBV-001 has limited use as an independent control peptide for association analysis.  
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Successful development of effective therapeutic vaccines for cancer has proven to be 
particularly challenging.  In the context of GBM, the most advanced therapeutic vaccine 
approach was that of rindopepimut (CDX-110) which consists a single 14-mer peptide 
derived from epidermal growth factor receptor variant III deletion mutation (EGFRvIII) (46). 
Results from a Phase II single arm study of rindopepimut, given to newly diagnosed 
EGFRvIII+ GBM patients post-CRT in combination with adjuvant TMZ, demonstrated a 
median OS of 21.8 months, an increase in anti-EGFRvIII antibody titer and clearance of 
EGFRvIII from the majority of analyzed post-treatment tumors (47). Even so, the resulting 
pivotal, double-blind, randomized, Phase III trial using the same schedule and setting was 
terminated at a planned interim analysis due to emergent data indicating that the study 
would not reach statistical significance for the primary OS endpoint (48). It is currently 
unclear as to why the study failed to meet the primary endpoint, albeit a median OS of 21.1 
months was reported for the placebo treated group (versus 20.4 months for vaccinated), 
well above the expected median of approximately 16 months, which may have confounded 
the data. A previous report suggests that GBM patients taking part in US based Phase II 
trials have significantly longer survival compared to historical data (49). The authors 
speculate that this may be due to the novel agent being tested or advances in standard of 
care. If the latter is correct, the apparent improvement in survival found in the Phase II 
rindopepimut study may have lead to an overly optimistic prediction of clinical benefit and 
subsequent failure of the Phase III trial. It is also possible that the reported loss of EGFRvIII 
from tumors during the vaccination period may have led to escape from immune 
surveillance, an issue that the IMA950 vaccine attempts to address by simultaneous 
targeting of 11 different antigens (TUMAPs). Nevertheless, even though the study reported 
here clearly met predefined immune response success criteria, further clinical optimization 
should precede transition of IMA950 into the next phase of clinical development. This 
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should include selection of the most appropriate adjuvant(s) and gaining a deeper 
understanding of how best to combine IMA950 with other immunotherapies, such as 
immune checkpoint inhibitors, in order to maximize the magnitude of immune response, as 
well as gaining a better understanding as to the optimal position and schedule of the 
vaccine relative to the current standard of care.  
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Table 1. Patients’ Baseline Characteristics 
Characteristic Cohort 1 Cohort 2 Overall 
Age, years  
Median 54 49 53 
Range 21 – 75 20 – 68 20 - 75 
Sex, No. (%)  
Male 15 (68%) 15 (65%) 30 (67%) 
Female 7 (32%) 8 (35%) 15 (33%) 
Total 22 23 45 
WHO performance status, No. (%)  
0 16 (73%) 8 (35%) 24 (53%) 
1 6 (27%) 15 (65%) 21 (47%) 
MGMT methylation status, No. (%†)  
Methylated 8 (42%) 3 (16%) 11 (29%) 
Unmethylated 11 (58%) 16 (84%) 27 (71%) 
Unavailable 3 4 7 
Lymphocyte count, x109/L  
Median 1.49* 0.80* 1.12 
Range 0.88 – 2.50 0.35 – 1.91 0.35 – 2.50 
Concomitant steroid use, No. (%) 
Yes 16 (73%) 17 (74%) 43 (73%) 
Entry concomitant steroid dose, mg  
Median 2.0 1.5 2.0 
Range 0 – 4.0 0 – 4.0 0 – 4.0 
Abbreviations: WHO, World Health Organization; MGMT, O6-Methylguanine DNA 
methyltransferase. 
† Percentages calculated excluding those patients whose MGMT methylation status was 
unavailable. 
* Significantly different lymphocyte counts between the two cohorts; p < 0.0001, two-tailed Man-
Whitney test. 
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Table 2. Most Common Adverse Events Occurring in >20% Patients (regardless of 
causality) 
 Grade, No. Total 
Symptom* 1 2 3 4 No. (% pts) 
Nausea 21 6 0 0 27 (60%) 
Injection Site Reaction 24 2 0 0 26 (58%) 
Fatigue 16 5 4 0 25 (56%) 
Headache 20 2 0 0 22 (49%) 
Vomiting 16 4 1 0 21 (47%) 
Alopecia 8 8 0 0 16 (36%) 
Dizziness 11 3 0 0 14 (31%) 
Seizure 4 4 3 2 13 (29%) 
Cough 9 2 0 0 11 (24%) 
Abbreviations: pts, patients. 
* Patients may have experienced multiple AEs of the same type. 
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Figure Legends 
Figure 1. Primary Immune Response Summary.  (A) Further development is based on: * 
>60% of patients being single or † >30% of patients being multi-TUMAP responders. (B) 
The number of vaccine-induced TUMAP responses is shown for the overall immune 
evaluable patient population (n=40) as well as for study cohorts. Black lines indicate mean 
values. For statistical analysis the Mann-Whitney test was used. 
Abbreviations: HBV, hepatitis B virus-derived vaccinated marker peptide; TUMAP, tumor 
associated peptide; VI, vaccine induced. 
 
Figure 2. Onset and sustainability of vaccine induced immune responses.  (A) Onset 
(first appearance) of vaccine-induced immune responses to IMA950 TUMAPs (n=77 total 
detected vaccine-induced responses in n=40 immune evaluable patients). (B) The 
percentage of vaccine-induced responses to IMA950 TUMAPs with detection at one, two or 
three post-vaccination assay time points. p-values were calculated using the Fisher’s exact 
test (only significant results are shown). 
Abbreviations: TUMAP, tumor associated peptide; VI, vaccine induced. 
 
Figure 3. Correlation of pre-treatment levels of regulatory T cells with vaccine-
induced immune responses to IMA950 TUMAPs. Treg (CD4+/CD25hi/CD127lo/FoxP3+) 
levels, normalized to lymphocytes, at V1 were analyzed in correlation with vaccine-induced 
CD8 T-cell responses to IMA950 TUMAPs in (A) all immune evaluable patients with n=40, 
(B) study Cohort 1 with n=19 and (C) study Cohort 2 with n=21. Correlation coefficients and 
p-values, calculated using Spearman’s correlation, are indicated on each graph. (D) Cohort 
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comparison of pre-treatment Treg levels on the first vaccination day for immune evaluable 
patients. For statistical analysis the Mann-Whitney test was used. 
Abbreviations: Treg, regulatory T cells; TUMAP, tumor associated peptide; V1, vaccination 1. 
 
Figure 4. Overall survival from date of surgery for different patient sub-sets. A) 
Median OS was 15.3 months for all patients (n = 44), 14.4 months for patients in Cohort 1 
(n =22) and 15.7 months for patients in Cohort 2 (n = 22). There was no significant 
difference between each of the cohorts (p = 0.63, Log-rank test); one patient was lost for 
follow up in Cohort 2 and excluded from survival analysis. B) Relationship between survival 
and TUMAP response. Only patients that were immune evaluable were included in the 
analysis. Log-rank test was used to calculate significance between the two different patient 
populations. C) Relationship between overall survival and injection site reaction. One 
patient was lost to survival follow up and is excluded from the analysis. Log-rank test was 
used to calculate significance and hazard ratio. Median age of patients in the ISR group 
was significantly lower than that of the non-ISR (47 versus 57 years respectively; p = 0.023 
by Mann Whitney test). 
Abbreviations: HR, hazard ratio; ISR, injection site reaction; TUMAP, tumor associated 
peptide; y, years. 
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